Brainsway Ltd.

Investor Presentation • Aug 13, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-35165

BRAINSWAY LTD. (Translation of registrant's name into English)

16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem, 9777516, Israel (+972-2) 582-4030

(Address and telephone number of Registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333- 230979) and the Company's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).

EXHIBIT INDEX

Exhibit Title

99.1 Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRAINSWAY LTD. (Registrant)

Date: August 13, 2025 /s/ Hadar Levy

Hadar Levy Chief Executive Officer

A New Era in Brain Disorder Treatment Corporate Presentation Nasdaq/TASE: BWAY August 2025

Disclaimer

Safe Harbor and Non-GAAP/IFRS Financial Measures

This presentation does not constitute and or issue, or any soliciation of an offer on acquir any of the Conpary securies or oparicipal in aranty in varanty in varanty in the accuracy or completenes of this presentation and assessment of the maters contained heein. In particular, no representation or waranty is given and the Company has no responsibility, as to the aches of any forecass, estimates, or statements as to prospects contained or referred to in this presentation

This presentation contains includes or is based on forward-ooking statements within the meaning of the federal securities aw. These statements are not guarantees of future performance, are based on current expectations of future to various risks and uncertainties that could cause our actual activities, ining or results to difter materially from those expressed or in such statements. Such factors inted to: continued business inpact from the COVD-19 global pandenic; weskening of economic conditions that could adversely affect the level of demand for our presures generally, difficulties or delays in manufacturing; banges in reinbursenent level from third-party payors; product liablify the impact of federal legislation to reform the United States healthcare system; changes in financial markets; c the competive environment; fallure to gain of our product; requatory actions or delay; and our ability to realize anticipated operational and manufacturing efficiencies. Additional information concerning the Rix Factors set forth therein, is contained in our filings with the U.S. Securities and Exchange Commisson. The forward-looking statements in the based upon our curent expectations. If one or nore of thee facors materialize, or f any underlying assumptions prove incorrect, our actual results performance or any vary materially from any tuture results, performance or achievements expressed or inplied by these foward-looking statements. You should not plance on forward-looking statements as a prediction of actual results. In addition, the presentation contains certain data and information that we obtained from various goverment and private publications also include projections based on a number of assumption. If any one or nore of the assumptions inderling the market data are later four may differ from the projections based on these assumptions. You should not place under elease on these fonward-looking statements included in this presentation are mate only as of the dated this preemation. We assune no obligation to update arg

Certain non-GAR/FRS finarcial neasures are included in this are designed to complement the financial information presented in accordance with FFS, because with FFS, because w managener thelleves such measure are use, we believe that Adjusted ERTDA, a non-life ele lin enalutin enalutin exalumin and ligation one lingation and ligation experess, tha substantialy from company and (b) managenet use Adjusted EBTDA in conjuntion who mores for dinance only as presearcion of on measures provided in accordance with IFRS. Other companies may calculate similarly titled non-GAAP/FRS financial measures differently than the Company.

Corporate Presentation May 2025

BrainsWay (BWAY) at a Glance

Advancing Neuroscience to Improve Health and Transform Lives

• / BrainsWay is a fast-growing global leader in advanced noninvasive neurostimulation treatments for mental health disorders
• V First and only TMS company to obtain 4 FDA-cleared indications (MDD, OCD, Anxious Depression, Smoking Addiction)
• Transition to a recurring revenue model through rentals and pay-peruse agreements, providing predictable and sustainable cash flow
• V Backlog and remaining performance obligations \$62 million
• V Broad reimbursement among commercial and governmental payors
• Global presence in key markets including the U.S., Canada, Asia, India, and Europe
• Proven, differentiated noninvasive neurostimulation platform technology
• Strong balance sheet with ~\$78 million in cash and no debt
• / NASDAQ: BWAY; MC: \$230M

Corporate Presentation August 2025

Strategic Partnership with Valor Equity Partners

Valor's Support Strengthens Our Position as a Leader in the TMS Industry

Q2 2025 Executive Summary

• · Revenue: \$12.6M, up 26% YoY
• · Operating income totaled \$0.6 million and Adjusted EBITDA rose to \$1.5 million
• · Net Profit: \$2M up 240% YoY
• · Remaining performance obligations increased by 25 % YOY to \$62 million
• · Eight consecutive quarters of positive free cash flow
• · Raised full-year 2025 Revenue and EBITDA guidance
• · 70% of recent customer engagements are structured as multi-year lease agreements
• · Cash Position: \$78.3M in cash and short-term deposits, no debt
• · 88 systems shipped in Q2 2025, up 35% YoY
• · Installed base: Reached +1,522 systems globally
• · Stella MSO: Completed equity financing with a top-performing clinic network
• · Several opportunities currently being explored
• · FDA Submission: Accelerated MDD and adolescence submitted for review
• · PTSD Expansion: Collaboration with Israel's Ministry of Defense for soldiers

Corporate Presentation August 2025

How Do We Partner?

Flexible Business Model Leads to Better Adoption

Lease: ~60%

Creates long-term stable revenue stream for BrainsWay Unlimited use with a fixed annual fee; 4-5 year contracts

MDD / OCD

Direct purchase: ~ 30%

One time purchase; maintenance fee for the following years Mainly through distribution channels

Growth Incentive model: ~10%

Reduces upfront capital commitment for physicians Pay-per-use fee; 4-5 year contracts

Corporate Presentation May 2025

Revenue & Adjusted EBITDA

Strong RPO Drives Clear Visibility Into Future Growth

Strategic Partnership with Stella

• √ 5\$M minority investment in Stella a leading U.S .- based interventional psychiatry platform
• Structured as a preferred, compounding equity stake
• √ Joint business planning and strategic growth support

> About Stella

• J 20+ clinics across the U.S. and Israel

• 30,000+ patients treated to date

• V Known for clinical excellence, operational strength, and innovative care delivery

& Stella Mental Health

Expanding Market Opportunities with Potential New Indications

1) Note: Other than MDD, CCD, and Smoking Addications are currently investigational, not available in the U.S., and not cleared by the FDA

Corporate Presentation August 2025

BrainsWay in Use

Academic Institutions and Private Clinics Worldwide Use BrainsWay Technology

Continuum of Care for Depression and OCD

Major Depressive Disorder		Obsessive-Compulsive Disorder
21 m Clinical Depression Sufferers/year2 60-90% comorbid anxiety symptoms3	Primary Care / Psychiatry	3m Obsessive-Compulsive Disorder Sufferers/year-
7m Treatment-Resistant Patients who do NOT achieve remission after 4 courses of medications & psychotherapy4	Intensive /	1.5m Treatment-Resistant Patients who do NOT respond to any medications or psychotherapy>>
Deep TMSTM (Transcranial Magnetic Stimulation)	Interventional Psychiatry	Deep TMSTM (Transcranial Magnetic Stimulation)
ECT (Electroconvulsive Therapy)		Intensive Program (Intensive Outpatient, Residential, Hospitalization)
Invasive & Experimental (e.g. Deep Brain Stimulation)	Surgery	Invasive & Experimental (e.g. Deep Brain Stimulation)

Transcranial Magnetic Stimulation (TMS)

BrainsWay

Established Technology with Demonstrated Safety and Efficacy

Comprehensively Studied

Over 25,000 published papers on TMS8

How Does it Work?

• 1. An electromagnetic coil is placed over the scalp
• 1. A fast current is produced in the coil
• 1. Electromagnetic field is induced in the brain
• 1. Rapidly changing electric field in the brain, leading to axonal depolarization and action potentials
• 1. 2.5 times deeper than Standard TMS
• 1. Deeper and broader stimulation leads to activation of more neurons.

Evolution of TMS

TMS has Been Used for >35 Years with BrainsWay Pioneering Key Innovations

BrainsWay Deep TMS™ Advantages over Traditional TMS1

Depression Clinical Efficacy

BrainsWay

Substantial Body of Clinical Evidence Demonstrating Safety and Efficacy

OCD Clinical Efficacy

Only TMS System with Clinically Demonstrated Safety and Efficacy Outcomes

Smoking Addiction

Smokers Spend Nearly \$2B/year on Quitting and ~85% are Unsuccessful

28.3m U.S. Adult Smokers17

68% are Motivated to Quit

7.6m

Made Serious Quit Attempt using prescription medication or nicotine replacement therapy (NRT)

4.7m

Smokers who were NOT successful quitting with cessation medication or psychotherapy18

Deep TMS™M

Transcranial Magnetic Stimulation

Corporate Presentation August 2025

Double-Blind, Placebo-Controlled RCT19

Nearly 1 in 3 Quit for 4 Weeks 2 of 3 Completers at Week 6 Remain Quitters for Add'l 3 Months

• 260 adult patients highly addicted to smoking from 15 worldwide centers
• 70% previously failed 3+ quit attempts
• No systemic side effects or seizures reported 6

First TMS Addiction Clearance

Deep TMS 360: Pilot Study

Corporate Presentation August 2025

New Tool to Improve Cognitive Performance in Patients with Dementia & MCI*

Over 10 million people Single-Channel, Fixed Field Deep TMS are diagnosed with mild Fixed Field Deep TMS has had some success in patients . cognitive impairment with MCI/Dementia, but moderate results may be due to (MCI) or dementia in atrophy and neurodegeneration in these patients This results in insufficient brain engagement by current the U.S. TMS technology Current medications have low efficacy, T 1 primarily stabilize rather Multi-Channel, Rotational Field Deep TMS 360 than enhance cognition, Deep TMS 360 targeting the prefrontal cortex is uniquely . and cause debilitating suited for older adults with neurodegenerative conditions side effects (e.g. Gl and reduced neuroplasticity due to its greater efficiency issues, dizziness, sleep at activating neurons oriented in multiple directions. · Deep TMS is currently the only TMS technology FDAdisturbances). cleared for patient over 68 years - a prime demographic Activates for MCI and dementia

*Not FDA Cleared

Practice Development Program

Support Program Proven to Increase Device Utilization, Leading to Repeat Sales

New Territories

Geographic Expansion into Japan, Europe, and Other Asian Countries

Most Extensive and Broadest TMS Intellectual Property

Encompassing Core Technology and Applications

Q2 2025 Financial Review

Actual

Q2 2025

12,632

3,133

9,499

75.20%

2,344

4,940

1,637

8,921

(1,519)

1,451

11%

\$0.05

\$0.05

578

70 2,027 Actual

Q2 2024

10,005

2,468

7,537

75.33%

1,711

3,796

1,444

6,951

586

(117)

103

600

1,248

12%

\$0.02

\$0.02

Variance

2,627 26%

1,962 26%

96

30%

28%

S

665 27%

633 37%

1,144

193 13%

1,970

(1,402) 1198%

(33) -32%

1.435 239%

203 16%

0.03 168%

0.03 160%

Net Income 7th Quarter in a row

Diluted Net Income Per Share Corporate Presentation August 2025

Basic Net Income Per Share

USD in Thousands Revenues

Cost of Revenues

Research and Development Expenses

General and Administrative Expenses

Selling and Marketing Expenses

Total Operating Expenses

Operating Profit Finance Income, Net

Taxes on Income

% EBITDA

Net Income Adjusted EBITDA

Gross Profit

% Margin

28

H1 2025 Financial Review

	Actual	Actual	Variance
USD in thousands	H1 2025	H1 2024	S	0/0
Revenues	24.168	19.100	5.068	27%
Cost of Revenues	6.059	4.751	1.308	28%
Gross profit	18,109	14,349	3.760	26%
Gross Margin
Research and Development expenses	4.676	3,337	1.339	40%
Selling and Marketing expenses	9.102	7.623	1.479	19%
General and Administrative expenses	3.177	2.710	467	17%
Total Operating expenses	16.955	13.670	3.285	24%
Operating Profit	1.154	679	475	70%
Finance Income, net	(2.207)	(307)	(1.900)	619%
Income Tax expense	227	275	(48)	-17%
Net Income	3.134	711	2.423	341%
Adjusted EBITDA	2,746	1,963	783	40%
Basic Net Income Per Share	\$ 0.08	S 0.02	0.06	316%
Diluted Net Income Per Share	A 0.07	S 0.02	0.05	262%

Corporate Presentation August 2025

Q2 2025 Balance Sheet

USD in thousands	As of June 30,	As of March 31,	As of December 31,	Change vs. 03/25		Change vs. 12/24
	2025	2025	2024	S	0/2	S	%
ASSETS
Cash and cash equivalents	67,912	71,601	69,345	(3,689)	-5%	(1.433)	-2%
Restricted cash	251	271	271	(20)	-7%	(20)	-7%
Short-term deposits	10,087			10,087	100%	10,087	100%
Trade receivables, net	3,871	6,954	4,596	(3,083)	-44%	(325)	-16%
Inventory	4.190	4,680	4,426	(490)	-10%	(236)	-5%
Other current assets	3.179	1.150	1.032	2.029	176%	2.147	208%
Total Current Assets	89,490	84,656	79,670	4,834	6%	9,820	12%
Non-Current Assets	22,074	15,542	14,646	6,532	42%	7,428	51%
Total Assets	111,564	100,198	94,316	11,366	11%	17,248	18%
LIABILITIES AND EQUITY
Current Liabilities	25,508	16,846	15,346	8,662	51%	10.162	66%
Non-Current Liabilities	17,924	19,602	16,657	(1,678)	-9%	1,267	8%
Equity	68,132	63,750	62,313	4,382	7%	5,819	9%
Total Liabilities and Equity	111,564	100,198	94,316	11,366	11%	17,248	18%

BrainsWay Investment Highlights

Advancing Neuroscience to Improve Health and Transform Lives

BrainsWay Leadership Team

Hadar Levy Chief Executive Officer 25+ Years Med Device

Michael Cohen Vice President - US Sales 15 + Years Med Device Sales Corporate Presentation May 2025

Ido Marom Chief Financial Officer 20+ Years Finance

Yuval Gimshi

Dr. Gilead Moiseyev Chief Technology Officer 20+ Years Med Device Dev

Dor Hagai

Dr. Richard Bermudes Chief Medical Officer 15+ Years TMS Leadership

Dr. Colleen Hanlon Vice President - Int'l Sales Vice President - Operations Vice President - Medical Affairs Vice President - Marketing 15+ Years Med Device Sales

Moria Ben Soussan Vice President - R&D 15 + Years Med Device Dev

Ross Mitchell

Thank you!

Investor Contact: Ido Marom Chief Financial Officer Ido.Marom@BrainsWay.com

References

• 1. BrainsWay Data on File
• 1. The National Institute of Mental Health: nimh.nih.gov
• 1. Kesler RC, et al. Comorbidty of DSM-III-R major deperal population: results from the US National Comorbidty Survey Br J Psychiaty Suppl. 1996
• 1. Trived MH et al. STAR'D Study Team (2006), Evaluation of otepression using measurement-based care in STAR'D implications for clinical practice. Am J Psychiatry. 2006 Jan: 163(1):28-40.
• 1. Greist JH. The comparative effectiveness of treatments for obsessive-compulsive disorder. Bull Menninger Clin. 1998;62(4, suppl 14);A65-A81
• Marks I. Behavior therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry. 1997;42:1021-1027 6.
• Ballenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999;46: 1579–1594 7.
• Lawson McLean A. Publication trends in transcranial magnetic stimulation: a 30-year panorama. Brain Stimul. 2019 May-Jun;12(3); 619-627
• 1. BrainsWay Data on File; Depth, measured in phance toward brain center for which E-feld >= 100V/m for callbrated stimulator output. If measung from scalp surface, an additional 1.5 cm should be aded , in , et al., 2016 Deep Transcranial Magnetic Stimulation: Modeling of Different Coll Configurations. 63, 1543-1550.
• 1. Fiocchi, S., et. al., 2016. Modelling of the Electric Field Distribution in Deep Transcranial Magnetic Stimulation. 2016
• 1. Company estimates, references 3.4M adult MDD patients with insurance 33 sessions per patient with an average ession price of 570; Openheimer Research Report, 08/24/2020
• 1. Tendler, A, et al. Deep TMS H1 Coil reatment for de a analysis. Pychiaty Reserch. Vol 32, June 2023, 15179
• 1. Senova S, et al. Durabiliy of antidepressant response to repetit stimulation: Systematic review and meta-analysis. Brain Stimulation 12 (2019) 119 £28 14. Gersner R. et al. What is the durability of Deep TMS for Maior Depressive Disorder. Brain Stimulation 13 (2020) 1842-1862
• 1. Roth Y, et al. Real-world efficacy of deep TMS for obser. Post-marketing data collected from twenty-two clinical stes. Psychiatr Res. 2020 Nov 4,5002-3956(20)31065-7
• 16 . Harmelech T et al. Long-term outcomes of a course of deep TMS for treatment-resistant OCD. Brain Stimulation 15 (2022) 226e228
• 1. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation-fast-facts/index.html. Data as of 2018 for U.S. adults.
• 1. EY Parthenon Analysis 2018 https://www.smokefreeworld.org/sites/default/files/ey-p smoking cessation landscape analysis key findings.pdf
• 1. Zangen A et al. Repettive transcranial magnetic stimal multicenter double-blind randomized controlled trial. World Psychary, 2021 Oct;20(3):397-404
• 1. https://worldpopulationreview.com/country-rankings/depression-rates-by-country. Corporate Presentation March 2025

34